Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | USP1 | O94782 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31542329 | 0.93 | ALK (0.35) | HRH3GPR119ALKNOTCH1JAK1 | |
| SCHEMBL31542350 | 0.90 | GPR119 (0.40) | GPR119ALKNOTCH1IRAK4JAK2 | |
| SCHEMBL31542292 | 0.88 | NOTCH1 (0.36) | GPR119ALKNOTCH1IRAK4JAK2 | |
| SCHEMBL31542299 | 0.86 | ALK (0.33) | ALK | |
| SCHEMBL31542285 | 0.81 | ALK (0.40) | ALK | |
| SCHEMBL31542311 | 0.79 | GPR119 (0.40) | HRH3GPR119 | |
| SCHEMBL31542332 | 0.79 | EGLN2 (0.44) | GPR119IRAK4 | |
| SCHEMBL31542314 | 0.79 | P2RY14 (0.39) | HRH3GPR119 | |
| SCHEMBL31542301 | 0.78 | GPR119 (0.41) | HRH3GPR119JAK2 | |
| SCHEMBL31542290 | 0.76 | KDM1A (0.33) | ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025062330-A1 | HETEROCYCLIC COMPOUNDS AS CBP SELECTIVE DEGRADERS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-03-27 | — | — | WO | disclosed |